Hanoi (VNA) - Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in improving overall health and wellness.
The global healthcare leader has been named Honoree in Digital Health category of the 2025 CES Innovations Awards program, an annual competition powered by the US Consumer Technology Association to highlight outstanding design and engineering in consumer technology products around the world.
Earlier this month, the device manufactured with life-changing technology was brought to the Consumer Electronics Show 2025 held on January 5-10 in Las Vegas, the most populous city in the US state of Nevada.
Lingo is built off of the world-leading FreeStyle Libre continuous glucose monitoring technology now used by more than 6 million people with diabetes globally. One of Abbott’s CGM systems, FreeStyle Libre 3 also stands among the company’s many CES Innovation Awards won in recent years.
“Glucose is a powerful signal of your body's unique response to food and lifestyle,” Olivier Ropars, divisional vice president of Abbott's Lingo business, said in a news statement.
“Abbott's Lingo tracks your glucose 24/7, translating the data into insights and bridging the gap between traditional healthcare and preventative measures. Lingo empowers individuals to build new healthy habits and take control of their health and wellness,” he was quoted as saying in the statement issued in September 2024.
At the show, Abbott shared that Lingo would empower consumers aged 18 and older not on insulin who are looking to improve their overall health and wellness. The system consists of a biosensor that is worn on the back of the arm for up to 14 days and continuously streams glucose data to the Lingo app on a smart phone.
The system translates the body's reaction to food, exercise, and life's daily stressors into personal insights about metabolic trends to help people make informed decisions about their health.
It shows glucose graph, Lingo count that shows glucose spikes, food and activity logging, and personal insights comprising tailored recommendations based on food logged time of day and accrued Lingo count.
Additionally, the system provides Lingo challenges, which involves creating new habits and earning badges upon the completion of challenges and the establishment of new healthy habits.
Compelling published research shows that limiting glucose spikes and improving overall management of glucose offer people who do not have diabetes a number of health benefits, such as being proactive about future health, managing weight, improving sleep and improving mood.
EMPOWERING PEOPLE FOR BETTER LIFE
Lingo is part of Abbott’s healthcare businesses and products that also cover nutritionals, medicines, diagnostics, and medical devices, which help people live more fully at all stages of life.
Another Abbott product, the award-winning FreeStyle Libre has revolutionised the way millions of people worldwide manage their diabetes.
In 2022, FreeStyle Libre was honored as the “best of the best” since 1970 during the Prix Galien Golden Jubilee Awards. At the time, the recognition highlighted the impact of FreeStyle Libre on the lives of approximately 4.5 million people living with diabetes globally.
The FreeStyle Libre technology was brought into Vietnam in 2021. This is among the company’s diversified innovative healthcare solutions and products continuously made available in the country in Abbott’s 30 years presence in Vietnam.
In helping treat premature and newborn babies with patent ductus arteriosus (PDA), a heart defect that can develop soon after birth, the company has brought to Vietnam the Amplatzer Piccolo Occluder, a pea-sized device that helps doctors repair holes in the tiny hearts of premature and infants without riskier surgery.
Abbott has also made available in Vietnam its innovative Clinical Decision Support system, a diagnostic informatics solution that uses AI to help medical experts improve clinical management. The solution contributes to improved health screening by categorising patients based on data analysis, applying risk assessment algorithms, and providing better clinical interpretation.
Abbott and its foundation, the Abbott Fund, have provided over 280 billion VND (~12 million USD) in grants and product donations to address critical health issues, with focus on improving nutrition, training healthcare staff, strengthening health systems, assisting healthcare professionals in the pandemic frontline and expanding community education.
Those efforts and solutions contribute to advance healthcare and continously empower strength and health for the people throughout the nation./.
